Gastrointestinal Medicines · LP-080
Lactulose Syrup
Medicine dossier. Catalogue identity is separated from unresolved product-specific fields and from external scientific references.
Development record
This dossier integrates an archived editorial source review dated 2026-09-11. Website reconciliation does not constitute a new medical or regulatory review. Controlled product approval, use instructions and supply status remain unestablished.
- Portfolio reference
- LP-080Gastrointestinal Medicines
- Generic identity
- LactuloseSyrup
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Layers 01–02 · Evidence boundary
What this public record establishes — and what remains held.
- Portfolio reference
- LP-080
- Generic identity
- Lactulose
- Presentation
- Syrup
- Catalogue strength
- 3.35 g/5 mL
- Catalogue pack
- Bottle 100 mL / 200 mL
- Public status
- Development presentation
Layer 01 · Controlled catalogue facts
- Generic identity: Lactulose.
- Dosage form: Syrup.
- Catalogue strength / concentration: 3.35 g/5 mL.
- Catalogue pack: Bottle 100 mL / 200 mL.
- Catalogue category: Gastrointestinal Medicines; navigation placement is not authorisation evidence.
Layer 02 · Unresolved product-specific fields
- Residual sugar profile, excipients/preservatives, viscosity and measuring-device specification.
- Whether both bottle volumes are controlled/registered SKUs and any after-opening handling requirements.
- Approved indication, patient eligibility, dose/administration and contraindication wording for the exact product/jurisdiction.
- Storage conditions, shelf life, registration/market status, manufacturing route and current supply status.
02 · Variants
Preserve each catalogue row without inferring missing SKU relationships.
| Variant | Proposed strength / concentration | Dosage form | Presentation detail | Pack relationship | Evidence status |
|---|---|---|---|---|---|
| A | 3.35 g/5 mL | Syrup | — | Bottle 100 mL | Residual sugars/excipients and controlled SKU status require product-specific evidence. |
| B | 3.35 g/5 mL | Syrup | — | Bottle 200 mL | Residual sugars/excipients and controlled SKU status require product-specific evidence. |
The table reproduces or structures catalogue-level fields. It does not create an approved SKU, instruction or specification where the source record does not provide one.
03 · External reference context
Ingredient and dosage-form background
Lactulose is an osmotic laxative that helps retain water in the bowel. It also has a separate clinician-directed role in some patients with hepatic encephalopathy. These clinical contexts require different assessment and monitoring. A syrup concentration does not establish an appropriate treatment plan. This ingredient profile is educational and does not constitute Luang Pharma approved labeling, a claim about its sugar impurities or an individualized administration schedule.
Clinical context and therapeutic role
Constipation assessment should identify contributing medicines, diet, fluid intake, mobility and alarm symptoms. A clinician may choose lactulose when an osmotic approach is appropriate, while persistent problems warrant review of the cause. Use in liver disease requires specialist direction and assessment of mental status and fluid balance. A product page cannot distinguish hepatic encephalopathy from another cause of confusion. The exact liquid concentration and measuring device must be checked.
Selected safety context
Bloating, wind, cramps and diarrhoea can occur. Excessive diarrhoea may cause dehydration and electrolyte imbalance. Suspected bowel obstruction, unexplained severe pain or persistent vomiting needs evaluation before laxative use. Diabetes and particular inherited sugar-intolerance conditions may require a review of the actual formulation. New confusion in someone with liver disease requires prompt assessment. Do not assume that every lactulose product has the same excipient or residual-sugar profile.
Selected external context only. It is not a complete risk profile or Luang Pharma approved labelling. The exact authorised IFU/label and applicable professional guidance control product use.
Formulation, presentation and handling evidence
This is a proposed liquid oral presentation with a stated concentration. The liquid vehicle, sweeteners, preservatives and whether the medicine requires shaking must be verified from the final label. A liquid format does not, by itself, establish that all age groups are eligible.
Use the product’s appropriate calibrated oral measuring device and verify concentration each time a new bottle is supplied. Keep the cap and label intact. Follow the actual instructions for storage and any period after opening; do not transfer advice from another brand or concentration.
Final instructions, storage conditions, shelf life and any after-opening/in-use limits require the exact controlled product documentation; none is created from a comparator reference.
Points for professional review
A clinician or pharmacist should assess the cause of symptoms, alarm features and interacting medicines before selecting treatment. Persistent or recurrent symptoms require review. The exact authorized label determines formulation-specific administration and local restrictions.
04 · Layer 04 · Documentation gate
Controlled product documents must close the held fields.
Before this medicine record can support product-specific clinical, technical or supply claims, the exact finished-product documentation must resolve the held fields.
Finished-product specification and quantitative composition for each exact presentation.
Approved/controlled label or leaflet for the intended jurisdiction.
Controlled strength/form/pack SKU matrix and packaging artwork where more than one variant or presentation is listed.
Registration/market-status and manufacturing-site evidence for the exact presentation.
Editorial source check: archived record dated 2026-09-11.
Qualified product/medical review: Not recorded at B07d checkpoint
Approved Luang Pharma label: Not provided or established
Registration / availability / supply: not established by this public record.
05 · Layer 03 · Sources & review
External references are attributed, not adopted as Luang Pharma labelling.
| Source | Recorded revision / check | How it is used |
|---|---|---|
| NHS: LactuloseArchived source classification: public-health medicine reference | Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval, registration, equivalence, manufacturing evidence or supply evidence. |
External sources may describe authorised products, public-health guidance or device classes. They do not establish equivalence, approval, model performance, manufacturing status or supply eligibility for LP-080.
Professional enquiries
Request product-specific evidence for LP-080.
State the exact presentation or configuration, organisation, destination and evidence you need. The public portfolio record is not an offer of supply.